Vireo Growth Inc. (VREOF): Capital Expenditures
$28.32M
Year ended 2025-12-31
+72.0%
3-year compound annual growth
+27.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $28.32M | +142.2% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $11.69M | +135.6% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $4.96M | -10.8% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $5.56M | -69.2% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $18.04M | +113.6% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $8.45M | n/a | 2022-03-15, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $28.32M | +142.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $452.0K | -75.2% |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $34.0K | -76.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $3.44M | +133.8% |
Compare VREOF, LGND, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗